CryoLife Gains Angina Treatments In $22 Mil. Cardiogenesis Acquisition
This article was originally published in The Gray Sheet
Executive Summary
CryoLife’s planned $22 million acquisition of Cardiogenesis will add treatments for drug-resistant angina that the firm says are highly complementary to its existing cardiac surgery offerings.